3 reasons why Pfizer (NYSE:PFE) might be a great buy

Pfizer stock has struggled this year, while other pharmaceutical companies have done well. Should our author be looking at buying shares in Pfizer?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Scientist filling a needle

Image source: Getty Images.

Key Points

  • Pfizer stock is down since the start of the year, but the underlying business looks to be in good shape
  • The company has been reinvesting the money made from its COVID-19 vaccines and currently trades at a relatively low P/E ratio
  • I think that Pfizer stock could be a great investment for my portfolio at current levels

Shares in Pfizer (NYSE:PFE) are down this year. The stock currently trades around 10% lower than it did at the beginning of January.

I find the decline surprising. I don’t have specialist pharmaceutical knowledge – and that brings a degree of risk to an investment in Pfizer stock – but I can’t see that anything has been going significantly wrong with the business.

On the contrary, Pfizer seems to me to be going from strength to strength. Here are three reasons why I think that Pfizer stock might might be a great buy for my portfolio.


Pfizer has been working hard to grow its drug portfolio lately. Specifically, it’s been using the money it generated from its COVID-19 vaccine to make acquisitions.

The details of Pfizer’s acquisitions might be difficult for non-specialists like me to evaluate. But the important thing, to my mind, is that the company is investing in growth for the future.

Pfizer’s COVID-19 success also seems to be ongoing. Recent approval of its antiviral pill and the use of its vaccines in boosters for under-11s in the US looks set to generate significant cash for the business going forward.

Accordingly, the first reason I think Pfizer looks like a great investment opportunity for me is its ability to generate cash in the future.

Low P/E ratio

Pfizer stock currently trades at a price-to-earnings (P/E) multiple of just over 11. That’s significantly lower than the S&P 500 average, which is around 18.

Normally, I wouldn’t over-emphasise the importance of a low P/E ratio. But I think it might be significant in the current climate.

Rising interest rates have been exerting pressure on share prices this year. As interest rates increase, stocks that trade at higher P/E multiples start to look expensive.

By contrast, stocks with lower P/E ratios are shielded from this effect somewhat. The fact that Pfizer’s shares trade at a low P/E ratio is therefore my second reason for thinking that the stock could be a great investment for me.

Investment returns

In my view, Pfizer has a good record both as a company and as a stock. Over the last five years, Pfizer stock has been a solid investment.

The share price has increased by 65.8% since June 2017 and Pfizer has paid out $9.64 per share in dividends to shareholders. In addition, Pfizer shareholders received stock in Viatris, worth around $1 per share as a result of Pfizer disposing of its generic drug unit.

Past performance are not always indicative of future returns and there’s a risk that Pfizer might struggle to maintain its momentum. But I think that Pfizer’s historic success is indicative of a strong business and a competent management team that will set the company in good stead for the future.

Conclusion: a stock to buy?

I’d be happy buying shares in Pfizer at today’s prices for my portfolio. While pharmaceutical companies are complicated, I think there are reasons to think that the stock could perform well over time.

Pfizer is making investments in its drug portfolio, trading at a reasonable price, and looks like a strong operation with a capable management team. That’s enough for me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Should I invest in the FTSE 100 – or try to beat it?

Our writer has the option of investing in a FTSE 100 tracker fund. So why does he choose to buy…

Read more »

Young black woman walking in Central London for shopping
Investing Articles

£1,500 to invest in a Stocks and Shares ISA? Here’s how I’d do it

Our writer has been investing in his Stocks and Shares ISA. Here he details how he could put £1,500 in…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

2 top FTSE 100 shares I’d buy before the market rebounds!

Christopher Ruane identifies a pair of FTSE 100 shares that have both tumbled in the past year and that he…

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

Here’s why the next bull market may have already begun

The UK stock market has taken the Bank of England's interest rate hike in its stride and green shoots suggest…

Read more »

Gold medal
Investing Articles

No contest! Here’s my stock of the week

An update from this company offered some relief from the economic gloom. It's this Fool's stock of the week.

Read more »

Cogs turning against each other
Investing Articles

Scottish Mortgage shares are back on the rise: is now the time to jump onboard?

Scottish Mortgage shares have risen over 25% in the past 30 days. This Fool takes a look at why and…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Why do Lloyds shares seem so cheap?

Lloyds shares have been losing ground and now look cheap on some valuations. So why has our writer removed the…

Read more »

Investing Articles

How to invest in shares to help beat inflation

Soaring prices could well outstrip our investing returns this year. I think it's more important to find shares to beat…

Read more »